Diagnosis of neuroendocrine tumors: Histopatology, biochemical investigation, structural imaging. Positron emission tomografy radiopharmaceutical: Receptor-targeting radiopharmaceuticals, metavolism-targeted radiopharmaceuticals, imaging protocols. Indications for positron emission tomografy/CT: diagnosis, stating and restating; detection of unknown primary tumor, therapy stratification, evaluation of therapy response. Role of metabolic positron emission tomografy/CT.
Prasad V., Ambrosini V., Alavi A., Fanti S., Baum R.P. (2008). PET/CT in Neuroendocrine Tumors: evaluation of receptor status and metabolism. PHILADELPHIA : W.B. Sauders Company [10.1016/j.cpet.2009.04.010].
PET/CT in Neuroendocrine Tumors: evaluation of receptor status and metabolism
AMBROSINI, VALENTINA;FANTI, STEFANO;
2008
Abstract
Diagnosis of neuroendocrine tumors: Histopatology, biochemical investigation, structural imaging. Positron emission tomografy radiopharmaceutical: Receptor-targeting radiopharmaceuticals, metavolism-targeted radiopharmaceuticals, imaging protocols. Indications for positron emission tomografy/CT: diagnosis, stating and restating; detection of unknown primary tumor, therapy stratification, evaluation of therapy response. Role of metabolic positron emission tomografy/CT.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
